Ge Long Hui·2026-01-30 12:07Core Insights - The company, Junshi Biosciences (688180.SH), expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year increase of about 28.32% [1] - The projected R&D expenses for 2025 are around 1.353 billion yuan, reflecting a growth of 6.10% compared to the previous year [1] - The company anticipates a net loss attributable to shareholders of approximately 873 million yuan for 2025, which is a reduction of 31.85% from the previous year's loss [1] Revenue and Profitability - The expected revenue growth is primarily driven by increased sales of commercialized drugs, particularly the core product, Toripalimab injection (brand name: Tuoyi®) [2] - The net loss, after excluding share-based payment impacts, is projected to be around 799 million yuan, indicating a significant reduction of 37.62% year-on-year [1] Product Performance - Toripalimab injection has seen substantial sales growth in the domestic market, with all 12 approved indications included in the national medical insurance catalog [2] - The product is the only anti-PD-1 monoclonal antibody listed for the treatment of renal cancer, triple-negative breast cancer, and melanoma in the catalog [2] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including the U.S., EU, and several Asian countries [2]